Vitrakvi set to become EU’s first tissue-agnostic cancer drug

By Sandi Wong, Staff Writer | Jul 27, 2019 | 12:05 AM GMT

EMA's CHMP delivered its first positive recommendation for a tissue-agnostic cancer therapy to Vitrakvi in its monthly basket of positive opinions, which also included one for GW’s Epidyolex.

CHMP backed approval of an MAA from Bayer AG (Xetra:BAYN) for Vitrakvi larotrectinib to treat